Sun Pharma presents clinical insights into specialty medicines; stock trades flat

These data analyses were presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020, June 12-June 14.

Jun 15, 2020 10:06 IST India Infoline News Service

Sun Pharma
Sun Pharmaceutical Industries Ltd announced that one of its wholly-owned subsidiaries presented data analyses for two of its specialty medicines –ODOMZO (sonidegib) and LEVULAN KERASTICK (aminolevulinic acid HCl) + BLU-U – from its dermatology portfolio, providing insights to healthcare providers treating patients who have or are at risk for different types of skin cancer. These data analyses were presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020, June 12-June 14.

The stock is currently trading at Rs478.65, down by Rs1.15 or 0.24% from its previous closing of Rs479.80 on the BSE.

“With incidence rates increasing and more treatment options needed, we are committed to providing clinical support for our medicines and helping address the needs of patients who are impacted by the different stages of skin cancer,” said Nicholas Squittieri, M.D., Senior Medical Director, Sun Pharma. “The evidence presented at the AAD Virtual Meeting Experience offers important insights and guidance to dermatology healthcare providers who are using ODOMZO and LEVULAN in their daily clinical practice.”

LEVULAN KERASTICK is the only photodynamic therapy medicine approved by the US FDA for use on the upper extremities.

Related Story

Open Free Demat Account (Rs699)
Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity